Lashkevich V A
Vopr Virusol. 2013 Jan-Feb;58(1):4-10.
In 1958 Poliomyelitis Institute in Moscow and Institute of Experimental Medicine in St. Petersburg received from A. Sabin the attenuated strains of poliomyelitis virus. The characteristics of the strains were thoroughly studied by A. A. Smorodintsev and coworkers. They found that the virulence of the strains fluctuated slightly in 10 consecutive passages through the intestine of the non-immune children. A part of the Sabin material was used by A. A. Smorodintsev and M. P. Chumakov in the beginning of 1959 for immunizing approximately 40000 children in Estonia, Lithuania, and Latvia. Epidemic poliomyelitis rate in these republics decreased from approximately 1000 cases yearly before vaccination to less than 20 in the third quarter of 1959. This was a convincing proof of the efficacy and safety of the vaccine from the attenuated Sabin strains. In 1959, according to A. Sabin's recommendation, a technology of live vaccine production was developed at the Poliomyelitis Institute, and several experimental lots of vaccine were prepared. In the second part of 1959, 13.5 million children in USSR were immunized. The epidemic poliomyelitis rate decreased 3-5 times in different regions without paralytic cases, which could be attributed to the vaccination. These results were the final proof of high efficiency and safety of live poliomyelitis vaccine from the attenuated Sabin strains. Based on these results, A. Sabin and M. P. Chumakov suggested in 1960 the idea of poliomyelitis eradication using mass immunization of children with live vaccine. 72 million persons up to 20 years old were vaccinated in USSR in 1960 with a 5 times drop in the paralytic rate. 50-year-long use of live vaccine results in poliomyelitis eradication in almost all countries worldwide. More than 10 million children were rescued from the death and palsy. Poliomyelitis eradication in a few countries where it still exists depends not on medical services but is defined by the attitude of their leaders to fight against poliomyelitis. In some developing countries the vaccination data are falsified, thereby threatening the polio epidemics reappearance and the virus spreading to other countries. Methods must be developed for detection and dealing with extremely rare persistent virus carriers. Because of all these constraints the outcome of poliomyelitis eradication at present is uncertain and vaccination must be continued. The world has become poliovaccine dependent.
1958年,莫斯科的脊髓灰质炎研究所和圣彼得堡的实验医学研究所从A. 萨宾处获得了脊髓灰质炎病毒减毒株。A. A. 斯莫罗金采夫及其同事对这些毒株的特性进行了深入研究。他们发现,这些毒株在连续10次通过非免疫儿童肠道传代过程中,毒力略有波动。1959年初,A. A. 斯莫罗金采夫和M. P. 丘马科夫使用了部分萨宾的材料,为爱沙尼亚、立陶宛和拉脱维亚的约4万名儿童进行免疫接种。这些共和国的脊髓灰质炎流行率从接种疫苗前每年约1000例降至1959年第三季度的不到20例。这令人信服地证明了萨宾减毒株疫苗的有效性和安全性。1959年,根据A. 萨宾的建议,脊髓灰质炎研究所在莫斯科开发了活疫苗生产技术,并制备了几批实验用疫苗。1959年下半年,苏联有1350万儿童接种了疫苗。在不同地区,脊髓灰质炎流行率下降了3至5倍,且无麻痹病例,这可归因于疫苗接种。这些结果最终证明了萨宾减毒株活脊髓灰质炎疫苗的高效性和安全性。基于这些结果,A. 萨宾和M. P. 丘马科夫在1960年提出了通过给儿童大规模接种活疫苗来根除脊髓灰质炎的想法。1960年,苏联有7200万人接种了疫苗,麻痹率下降了5倍。50年来,活疫苗的使用使全球几乎所有国家都根除了脊髓灰质炎。1000多万儿童因此免于死亡和瘫痪。在少数仍存在脊髓灰质炎的国家,根除工作并非取决于医疗服务,而是取决于其领导人对抗脊髓灰质炎的态度。在一些发展中国家,疫苗接种数据被伪造,从而威胁到脊髓灰质炎疫情的再次出现以及病毒向其他国家的传播。必须开发检测和处理极其罕见的持续病毒携带者的方法。由于所有这些限制因素,目前根除脊髓灰质炎的结果尚不确定,必须继续进行疫苗接种。世界已变得依赖脊髓灰质炎疫苗。